Regulator Warns Of Tougher Pricing Regime In India Amid ‘Market Failure’

 
• By Anju Ghangurde
  
Generate a summary of this article
Listen to this article
Beta

India’s apex pricing authority concludes some in Rx industry have not played 'fair'; 25% of products show market failure, Bhupendra Singh says.

MT1702_Red-signal-light_railway-crossing_1200x675
INDIA'S PRICING REGULATOR HAS HINTED AT A TOUGHER PRICING REGIME TO COME

Expect a tougher drug pricing regime in India, and the apex pricing regulator has a hawk eye on industry tactics that may distort market dynamics and impact the affordability of healthcare in the country. Those were some of the broad takeaways from National Pharmaceutical Pricing Authority (NPPA) chair Bhupendra Singh’s address at the 56th annual day celebrations of the Indian Drug Manufacturer’s Association (IDMA).

A stricter pricing policy approach in India could further up the challenges of the pharmaceutical industry, especially for domestic firms...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Legislation

Coping Strategies For China Industry Amid BIOSECURE Overhang

 
• By Xu Hu

With the US BIOSECURE Act waiting for a Senate vote, there are signs it may be prompting some Chinese firms to look at their operations. In the meantime, two legal experts in China suggest a range of coping strategies for companies that may be deemed "of concern."

EU Pharma Reform: What You Need to Know Now

 
• By Anabel Costa-Ferreira and Ian Schofield

As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

PBM Legislation: Medicare Rebate Reform May Be Challenging Amid Disruption From Redesign

 
• By Cathy Kelly

US lawmakers will undoubtedly continue to work on pharmacy benefit manager reform legislation in 2025, given its bipartisan support. But policies impacting rebates that could lead to higher premiums in Part D may be a tough sell in the midst of the benefit redesign.

US Presidential Elections: Are Prescription Drug Pricing Reforms Losing Political Luster?

 
• By Cathy Kelly

Neither Kamala Harris nor Donald Trump mentioned drug pricing reforms in their presidential convention speeches.

More from Pink Sheet

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’

 
• By Sue Sutter

Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’

Nancy Tests New Podcast Template

 
• By Derrick Gingery

Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.

PinkSheet-R&D-Free: ‘Ranking’ article that includes different Composer content

 
• By Nabil, Olga Zviezdicheva, Reed Miller, Mary Jo Laffler, Ian Schofield, João Andrés-Ruíz de la Fontaine-LeBlanc, Chloë Anastasía-Stojanović del Castillo-Ribeirão, and Nabil

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.